Apart from targeting cisplatin-resistant cancer cells to address chemoresistance issue, Teixeira, R. G et al. proposed a novel approach that organometallic Ru(II) compounds increased cisplatin cytotoxicity up to 1390-fold at nontoxic doses by inhibiting multidrug resistance-associated protein 1 (MRP1) and the P-glycoprotein 1 (Pgp) transporters [87]. The gene discussed is ABCC1; the disease is cancer.